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for 48h and were treated with various concentrations (250µM-2.0µM) of AVR-25 serially diluted to half (in triplicates). ELISA was performed after 48h of incubation on the cell lysate following the manufacturer instruction. IC50 of the AVR-25 for TLR4 binding was calculated using GraphPad Prism7.04. (N = 3.) and found to be 0.156 µM.
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Fig. S2:
Compound AVR-25 binds to TLR4 but not to TLR2: Briefly, 0.5 million human PBMC (LeukoPak) were plated in 96 well plates and after 8-10h incubation at 37 o C non-adherent cells were removed. Adherent cells were treated with 10µM of the compounds in PBS and incubated for 48h. TLR2 and TLR4 ELISA was performed on the cell lysate following the manufacturer's instruction. *p<0.01, **p<0.001 (N = 3). Histology scoring was performed for each individual tissue. The following cells in each of the organs was scored on the total percentage of area damage: Heart (Myocardium), Lung alveoli, Kidney (glomeruli, tubules), Spleen (lymphoid follicles), Liver (Hepatocyte), Brain (Neuronal Damage), Testis (Seminiferous tubules) and Ovary (Follicles). Vascular congestion and hemorrhage were assessed by the number of areas/High power field (HPF). The following scoring system was followed: 3.5 ± 0.13 3.7 ± 0.12 0.6 ± 0.13
